open access

Vol 18, No 4 (2014)
Review paper
Published online: 2015-03-25
Get Citation

Arterial hypertension treatment in elderly

Katarzyna Pawlaczyk-Gabriel, Arkadiusz Niklas, Paweł Uruski, Andrzej Tykarski
Nadciśnienie tętnicze 2014;18(4):211-223.

open access

Vol 18, No 4 (2014)
REVIEV
Published online: 2015-03-25

Abstract

It is anticipated that over the next 45 years the global population of the globe will increase from 6 to 9 billion. This increase, however, is not associated with the growth of the birthrate but with increases in life expectancy. This situation leads consequently to an increase in the population percentage of adults and the elderly. The prevalence of hypertension increases with age. According to the guidelines of the Polish Society of Hypertension (PTNT) of 2011 and the guidelines of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) of 2013, criteria for hypertension diagnosis in the elderly are the same as in the general population. There is a consensus in the recommendations for the treatment of hypertension that its primary goal is to reduce total and cardiovascular mortality and risk of major cardiovascular events (myocardial infarction, heart failure, stroke) and renal failure. Following the recommendations of the various societies, the target pressure values in the elderly should be < 140/90 mm Hg. However, the HYVET trial results shed some light on slightly different antihypertensive treatment in the population > 80 years of age. On this basis, it was found that in patients over 80 years old, who are not burdened with multiple comorbidities, antihypertensive therapy should be initiated when SBP > 160 mm Hg. Careful management of these patients shows that the target threshold below which SBP should be reduced is 150 mm Hg. Especially in the elderly, it is very important to individualize the antihypertensive therapy, based i. a. on the clinical condition of the patient.

Abstract

It is anticipated that over the next 45 years the global population of the globe will increase from 6 to 9 billion. This increase, however, is not associated with the growth of the birthrate but with increases in life expectancy. This situation leads consequently to an increase in the population percentage of adults and the elderly. The prevalence of hypertension increases with age. According to the guidelines of the Polish Society of Hypertension (PTNT) of 2011 and the guidelines of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) of 2013, criteria for hypertension diagnosis in the elderly are the same as in the general population. There is a consensus in the recommendations for the treatment of hypertension that its primary goal is to reduce total and cardiovascular mortality and risk of major cardiovascular events (myocardial infarction, heart failure, stroke) and renal failure. Following the recommendations of the various societies, the target pressure values in the elderly should be < 140/90 mm Hg. However, the HYVET trial results shed some light on slightly different antihypertensive treatment in the population > 80 years of age. On this basis, it was found that in patients over 80 years old, who are not burdened with multiple comorbidities, antihypertensive therapy should be initiated when SBP > 160 mm Hg. Careful management of these patients shows that the target threshold below which SBP should be reduced is 150 mm Hg. Especially in the elderly, it is very important to individualize the antihypertensive therapy, based i. a. on the clinical condition of the patient.

Get Citation

Keywords

hypertension treatment, isolated systolic hypertension, HYVET trial, hipertensive therapy individualisation

About this article
Title

Arterial hypertension treatment in elderly

Journal

Arterial Hypertension

Issue

Vol 18, No 4 (2014)

Article type

Review paper

Pages

211-223

Published online

2015-03-25

Page views

1092

Article views/downloads

3060

Bibliographic record

Nadciśnienie tętnicze 2014;18(4):211-223.

Keywords

hypertension treatment
isolated systolic hypertension
HYVET trial
hipertensive therapy individualisation

Authors

Katarzyna Pawlaczyk-Gabriel
Arkadiusz Niklas
Paweł Uruski
Andrzej Tykarski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl